Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > My Letter To Santa !!!

<< Previous

Bullboard Posts

Next >>

Post by HighSkies2019on Feb 23, 2022 7:49pm

184 Views

Post# 34456024

My Letter To Santa !!!

Dear Bob ! You know I was a big fan of yours and still might be !!!...If tomorrow... which would be greatly appreciated if you really gave a NR that would create the stock price to rise...and I don't mean couple of pennies !!!.... I think I have held on long enough to believe ! If you do I might than reconsider how I feel about my feelings for you.! Thanking You in advance. H.S

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project